PMID- 29717512 OWN - NLM STAT- MEDLINE DCOM- 20181126 LR - 20181126 IS - 1540-8183 (Electronic) IS - 0896-4327 (Linking) VI - 31 IP - 5 DP - 2018 Oct TI - Impact of ultra-thin struts on restenosis after chronic total occlusion recanalization: Insights from the randomized PRISON IV trial. PG - 580-587 LID - 10.1111/joic.12516 [doi] AB - OBJECTIVES: The PRISON-IV trial showed inferior outcome in patients with chronic total occlusions (CTOs) treated with the ultrathin-struts (60 mum for stent diameter 3 mm) hybrid-sirolimus eluting stents (SES) compared with everolimus eluting stents (EES, 81 mum). The aim of this study is to investigate if the use of smaller stents (3 mm (Group-B, 59 patients), and those receiving stents of both sizes (Group-C, 93 patients). RESULTS: Baseline and procedural characteristics were comparable in the three groups. At angiographic follow-up, most of the adverse outcomes occurred in Group A, with higher incidence of binary restenosis in the Hybrid-SES versus EES (10.3% vs 1.3%, P = 0.03) and augmented in-stent diameter stenosis (26.04 +/- 18.59% vs 21.24 +/- 12.84, P = 0.06). Similarly, optical coherence tomography (OCT), which was performed in 60 patients at follow-up, documented a mild trend toward lower values of minimum in stent area in Hybrid-SES arm of Group A (4.4 +/- 1.02mm(2) vs 5.0 +/- 1.28mm2, respectively, P = 0.16). CONCLUSIONS: The present analysis suggests that the inferior performance of the ultra-thin hybrid-SES in CTO-PCI is particularly pronounced when smaller stent (